ModernGraham Valuation

Company Name:

Company Ticker DEPO Date of Analysis Depomed Inc





Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1.	Adequate Size of the Enterprise	Market Cap > \$2Bil	\$372,264,874	Fail
2.	Sufficiently Strong Financial Condition	Current Ratio > 2	0.79	Fail
3.	Earnings Stability	Positive EPS for 10 years prior		Fail
4.	Dividend Record	Dividend Payments for 10 years prior		Fail
5.	Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	354.41%	Pass
6.	Moderate PEmg Ratio	PEmg < 20	-13.37	Fail
7.	Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	1.75	Fail
Enterprising Investor; mus	st pass 4 out of the following 5 tests, or be s	uitable for the Defensive Investor.		
1.	Sufficiently Strong Financial Condition	Current Ratio > 1.5	0.79	Fail

2. Sufficiently Strong Financial ConditionDebt to NCA < 1.1-9.53. Earnings StabilityPositive EPS for 5 years prior4. Dividend RecordCurrently Pays Dividend5. Earnings GrowthEPSmg greater than 5 years ago	1.	. Sufficiently Strong Financial Condition	Current Ratio > 1.5	0.79	Fail
4. Dividend Record Currently Pays Dividend	2.	. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	-9.55	Fail
	3.	. Earnings Stability	Positive EPS for 5 years prior		Fail
5. Earnings Growth EPSmg greater than 5 years ago	4.	. Dividend Record	Currently Pays Dividend		Fail
	5.	. Earnings Growth	EPSmg greater than 5 years ago		Fail
Score			Score		

Suitability

Defensive	No
Enterprising	No

Stage 2: Determination of Intrinsic Value

EPSmg		-\$0.44
MG Growth Estimate		-4.25%
MG Value		\$0.00
MG Value based on 3% Growth		-\$6.41
MG Value based on 0% Growth		-\$3.76
Market Implied Growth Rate		-10.94%
Current Price		\$5.91
% of Intrinsic Value	N/A	
Opinion	Overvalued	
MG Grade	D	
	MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate Current Price % of Intrinsic Value Opinion	MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate Current Price % of Intrinsic Value N/A Opinion N/A


Stage 3: Information for Further Research


Net Current Asset Value (NCAV)	-\$10.48
Graham Number	\$0.00
PEmg	-13.37
Current Ratio	0.79
PB Ratio	1.75
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend	
Growth	0

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate	-\$0.38	Next Fiscal Year Estimate	-\$0.44
Dec2016	-\$1.45	Dec2016	-\$0.34
Dec2015	-\$1.26	Dec2015	\$0.29
Dec2014	\$2.05	Dec2014	\$0.95
Dec2013	\$0.75	Dec2013	\$0.34
Dec2012	-\$0.53	Dec2012	\$0.09
Dec2011	\$1.26	Dec2011	\$0.38
Dec2010	\$0.07	Dec2010	-\$0.08
Dec2009	-\$0.43	Dec2009	-\$0.19
Dec2008	-\$0.32	Dec2008	-\$0.16
Dec2007	\$1.05	Dec2007	-\$0.22
Dec2006	-\$0.97	Dec2006	-\$0.88
Dec2005	-\$0.64	Dec2005	-\$0.91
Dec2004	-\$0.78	Dec2004	-\$1.11
Dec2003	-\$1.23	Dec2003	-\$1.26
Dec2002	-\$0.92	Dec2002	-\$1.21
Dec2001	-\$1.81	Dec2001	-\$1.23
Dec2000	-\$1.43	Balance Sheet Information	6/1/2017
Dec1999	-\$0.80	Total Current Assets	\$219,043,000
Dec1998	-\$0.44	Total Current Liabilities	\$278,941,000
Dec1997	-\$0.34	Long-Term Debt	\$572,050,000
		Total Assets	\$1,085,600,000
		Intangible Assets	\$850,679,000
		Total Liabilities	\$874,204,000
		Shares Outstanding (Diluted Average)	62,532,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company #N/A

Other ModernGraham Endo International PLC Valuation – July 2017 \$ENDP Biogen Inc Valuation - July 2017 \$BIIB posts about related . companies Mylan NV Valuation – March 2017 \$MYL Amgen Inc Valuation - March 2017 \$AMGN Celgene Corporation Valuation - March 2017 \$CELG Ligand Pharmaceuticals Inc Valuation - Initial Coverage \$LGND Pfizer Inc Valuation – March 2017 \$PFE Supernus Pharmaceuticals Inc Valuation – Initial Coverage \$SUPN Lannett Company Inc Valuation - Initial Coverage \$LCI

Spectrum Pharmaceuticals Inc Valuation - Initial Coverage \$SPPI